Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

What is Genetic Engineering?

What is Genetic Engineering?

Diversity of Antigen Receptors

Diversity of Antigen Receptors

Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...

T Cell Activation and Clonal Selection

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Characterization of occult hepatitis B virus infection from blood donors in China.

Journal of clinical microbiology·2011

Same author

Cardioprotective effects of Glycyrrhiza uralensis extract against doxorubicin-induced toxicity.

International journal of toxicology·2011

Same author

Nanoscale Kirkendall effect for the synthesis of Bi2MoO6 boxes via a facile solution-phase method.

Nanoscale·2011

Same author

p62/SQSTM1 involved in cisplatin resistance in human ovarian cancer cells by clearing ubiquitinated proteins.

European journal of cancer (Oxford, England : 1990)·2011

Same author

An excellent crystal for high resistance against optical damage in visible-UV range: near-stoichiometric zirconium-doped lithium niobate.

Optics express·2011

Same author

[Correlation of CD19 positive cell counts in bone marrow with therapeutic efficacy in patients with multiple myeloma].

Zhongguo shi yan xue ye xue za zhi·2011

Search research articles

Related Experiment Video

Updated: May 26, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Genetic engineering with T cell receptors.

Ling Zhang¹, Richard A Morgan

¹National Institutes of Health, National Cancer Institute, Surgery Branch, Bethesda, MD 20892, USA.

Advanced Drug Delivery Reviews

|December 20, 2011

Summary

Gene-engineered T cells targeting tumors show promise for cancer therapy. This approach enhances T cells to recognize and attack cancer cells, leading to tumor regression in early studies.

Area of Science:

Immunology
Oncology
Gene Therapy

Background:

Human gene transfer research has advanced significantly over the past 20 years, moving from lab to clinical applications.
Adoptive transfer of tumor-reactive lymphocytes has shown success in treating metastatic melanoma.
Genetic engineering of T cells with tumor antigen-specific T cell receptor (TCR) genes offers a new strategy to redirect T cells against cancer.

Purpose of the Study:

To review the progress and prospects of T cell receptor (TCR) gene-engineered T cells as a therapeutic strategy.
To discuss advancements in TCR gene transfer systems for cancer treatment.
To highlight the potential of TCR gene-engineered T cells for melanoma and other cancers.

Main Methods:

Optimization of gene expression and gene transfer protocols for TCR gene delivery.

More Related Videos

Retroviral Transduction of T-cell Receptors in Mouse T-cells

Retroviral Transduction of T-cell Receptors in Mouse T-cells

Published on: October 22, 2010

Generating De Novo Antigen-specific Human T Cell Receptors by Retroviral Transduction of Centric Hemichain

Generating De Novo Antigen-specific Human T Cell Receptors by Retroviral Transduction of Centric Hemichain

Published on: October 25, 2016

Related Experiment Videos

Last Updated: May 26, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Retroviral Transduction of T-cell Receptors in Mouse T-cells

Retroviral Transduction of T-cell Receptors in Mouse T-cells

Published on: October 22, 2010

Generating De Novo Antigen-specific Human T Cell Receptors by Retroviral Transduction of Centric Hemichain

Generating De Novo Antigen-specific Human T Cell Receptors by Retroviral Transduction of Centric Hemichain

Published on: October 25, 2016

Development of vector and protein modifications to improve TCR chain expression in human lymphocytes.

Reduction of mis-pairing between introduced and endogenous TCR chains.

Main Results:

TCR gene transfer systems have been significantly improved, enabling excellent expression of introduced TCR chains.
Vector and protein modifications minimize mis-pairing issues, enhancing therapeutic efficacy.
Initial clinical studies indicate that TCR gene-engineered T cells can induce tumor regression in vivo.

Conclusions:

TCR gene-engineered T cells represent a promising therapeutic strategy for cancer treatment, particularly melanoma.
Continued progress in gene transfer technology and clinical evaluation is expected to expand their application.
This approach holds potential for generating large numbers of defined antigen-specific cells for therapeutic use.